Stephan Mathas
Overview
Explore the profile of Stephan Mathas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Costanza M, Giordano C, von Brunneck A, Zhao J, Makky A, Vinh K, et al.
Br J Dermatol
. 2025 Mar;
PMID: 40036608
Background: Prognosis and quality of life of advanced cutaneous T cell lymphoma (CTCL) patients, in particular those with Sézary syndrome (SS) and advanced-stage mycosis fungoides (MF), are poor. Monoclonal antibodies...
2.
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, et al.
Lancet
. 2024 Jul;
404(10450):341-352.
PMID: 38971175
Background: Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With...
3.
Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, et al.
Mol Cancer
. 2024 May;
23(1):114.
PMID: 38811984
Background: Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncogenic...
4.
Schorb E, Isbell L, Kerkhoff A, Mathas S, Braulke F, Egerer G, et al.
Lancet Haematol
. 2024 Feb;
11(3):e196-e205.
PMID: 38301670
Background: Available treatments for older patients with primary diffuse large B-cell CNS lymphoma (PCNSL) offer progression-free survival of up to 16 months. We aimed to investigate an intensified treatment of...
5.
Schleussner N, Cauchy P, Franke V, Giefing M, Fornes O, Vankadari N, et al.
Nat Commun
. 2023 Nov;
14(1):6947.
PMID: 37935654
Disease-causing mutations in genes encoding transcription factors (TFs) can affect TF interactions with their cognate DNA-binding motifs. Whether and how TF mutations impact upon the binding to TF composite elements...
6.
Kouroukli A, Fischer A, Kretzmer H, Chteinberg E, Rajaram N, Glaser S, et al.
Blood Cancer J
. 2023 Jun;
13(1):98.
PMID: 37365157
No abstract available.
7.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H, et al.
J Clin Invest
. 2023 May;
133(12).
PMID: 37159273
BACKGROUNDAdoptive transfer of EBV-specific T cells can restore specific immunity in immunocompromised patients with EBV-associated complications.METHODSWe provide results of a personalized T cell manufacturing program evaluating donor, patient, T cell...
8.
Winkler W, Farre Diaz C, Blanc E, Napieczynska H, Langner P, Werner M, et al.
Proc Natl Acad Sci U S A
. 2023 Feb;
120(10):e2219439120.
PMID: 36853944
Multiple myeloma (MM), a tumor of germinal center (GC)-experienced plasma cells, comprises distinct genetic subgroups, such as the t(11;14)/CCND1 and the t(4;14)/MMSET subtype. We have generated genetically defined, subgroup-specific MM...
9.
Fornes O, Jia A, Kuehn H, Min Q, Pannicke U, Schleussner N, et al.
Sci Immunol
. 2023 Jan;
8(79):eade7953.
PMID: 36662884
Interferon regulatory factor 4 (IRF4) is a transcription factor (TF) and key regulator of immune cell development and function. We report a recurrent heterozygous mutation in IRF4, p.T95R, causing an...
10.
Brockelmann P, Buhnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth T, et al.
J Clin Oncol
. 2022 Dec;
41(6):1193-1199.
PMID: 36508302
JCO In the investigator-sponsored randomized phase II NIVAHL trial for early-stage unfavorable classical Hodgkin lymphoma (HL), two schedules of four cycles of nivolumab, doxorubicin, vinblastine, and dacarbazine followed by 30...